Effectiveness Analysis Registry between 2000 and 2007. Data were extracted on publication year, target population, intervention, patient sample, disease, prevention stage, and incremental cost-utility ratio of each economic evaluation. Preventive interventions were defined as measures preventing disease onset. Curative interventions related to measures identifying patients with risk factors or preclinical disease or interventions limiting disability after harm has occurred. Results were expressed in terms of costs (valued in 2008 Euro) per quality-adjusted life year. The association between incremental cost-utility ratios and prevention stage was examined by means of the Mann-Whitney U-test. RESULTS: The analysis included 231 studies that reported information about 608 incremental cost-effectiveness ratios. Preventive interventions included interventions that were more effective and less expensive than comparators (41% of incremental cost-effectiveness ratios), and interventions that improved outcomes and increased costs (59%). Both preventive and curative interventions covered the full range of cost-effectiveness results. However, preventive interventions had a significantly lower median ratio of 6,255 € per quality-adjusted life year and were thus more cost-effective than curative interventions (12,917 € per quality-adjusted life year) (p ϭ 0.002). CONCLUSIONS: Although the cost-effectiveness of preventive interventions varies substantially, preventive interventions tended to be more cost-effective than curative interventions.
OBJECTIVES:
In the light of the austerity drives and cost containment practices, payers increasingly resort to procurement procedures in order to award contracts for the supply of both conventional drugs and biosimilars. The tough reality of health care economics in conjunction with the commitment of large generic manufacturers, who continue to invest despite the challenges, may mean that tendering of biosimilars may actually be a tool to increase biosimilars' market share by demonstrating price competitiveness.This study aims to evaluate how initial list price, together with other considerations about efficacy and safety, could influence the hospital formulary inclusion of new biosimilar drugs in the UK. METHODS: A data framework was developed from secondary research of existing biosimilar list prices, product profiles, clinical data submitted and current landscape. The framework was validated through phone-based interviews across different regions in the UK (nϭ10) targeting Hospital procurement Pharmacists in 2011. RESULTS: Majority of respondents indicated price to be the primary criteria for formulary inclusion although some pharmacists highlighted efficacy and safety parameters as influencing factors CONCLUSIONS: The development of clinical commissioning consortia and the expansion of the biosimilar market as major biologicals come off patent mean that more decisions about biosimilar purchasing could be made jointly with primary care. Tendering as a mode of procurement for biosimilars, removes the prescriber's influence which is the acceptance-limiting step for biosimilars currently due to the concerns on efficacy and safety. From a hospital procurement pharmacists' point of view, it is unclear whether a price discount strategy will favour the introduction of new biosimilars in the UK hospitals as other factors might have a more important role in the final purchasing decision. 
PHP110 UTILIZATION OF PHYSIOTHERAPY SERVICES IN HUNGARY

OBJECTIVES:
Physiotherapy services are reimbursed on a fee for service method in the ambulatory care in Hungary. The aim of this study is to analyze the utilization of physiotherapy services in Hungary. METHODS: Data were derived from the financial database of the National Health Insurance Fund Administration, the only health care financing agency in Hungary. We analyzed the year 2008. Medical procedures which can be performed by physiotherapists were included into the study. Medical procedures are listed according to the Hungarian version of the International Classification of Procedures in Medicine of WHO. RESULTS: Altogether 151 medical procedures were used by physiotherapists. The following top-11 medical procedure were responsible for more than half (52.5 %) of total activities: ultrasound therapy (8.2 %), iontophorezis (6.5 %), muscle strengthening exercise (4.8 %), individual training (4.4 %), training for circulation improvement (4.1 %), hand massage (4.0 %), passive movement of multiple limb (4.0 %), middle frequency treatment (3.8 %), mobilization of joints (3.3 %), exercises against resistance (3.2 %), education of using medical devices (3.1 %), extension of contracture (3.1 %). Total annual health insurance reimbursement of physiotherapy services was 7.34 billion Hungarian Forint (42.7 million USD; 29.2 million EUR). CONCLUSIONS: Physiotherapy care proved to be a highly concentrated health service where 11 medical procedures out of 151 are responsible of more than half of activity and health insurance reimbursement. OBJECTIVES: ISPOR's mission is to increase the efficiency, effectiveness, and fairness with which the available health care resources are used to improve health together with a strong vision be recognized globally as the authority for outcomes research and its use in health care decisions towards improved health. Despite modest increases, the membership and conference attendance of health care decision makers still remains low, relative to those involved in academia, industry and consultancy. Assessing if some of those responsible for utilising HEOR data in care provision and care practice are aware of ISPOR and its full resources and the drivers and barriers for involvement could provide an opportunity for increased membership and active involvement. METHODS: To elucidate the level of awareness of ISPOR, its publications and other resources, interviews were undertaken with stakeholders within 12 NHS Cancer Networks in the UK. A data framework was developed to support a series of structured telephone interviews according to the British Healthcare Business Intelligence (BHBIA) Legal and Ethical Guidelines for Healthcare Market Research. RESULTS: Spontaneous awareness of ISPOR is relatively limited within the NHS Cancer Network stakeholders, with even less awareness to Value in Health. Notable areas of interest were Oncology, Patient Adherence and Persistence and Patient Reported Outcomes Measures. The main barriers to membership of ISPOR was its initial awareness and more effective involvement would be limited due to existing NHS commitments, financial resources and levels of individual interest /relevance to existing NHS role. Organisational involvement with NHS stakeholder networks would support increased levels of engagement. CONCLUSIONS: To enhance the awareness of ISPOR, its resources, conferences and educational support, ISPOR should consider a more targeted awareness campaign with key NHS clinical networks such as NHS Cancer Networks, British Oncology Pharmacy Association and evolving Clinical Commissioning Groups. OBJECTIVES: Therapeutic monoclonal antibodies (mAbs) are capturing an increasingly larger proportion of the pharmaceutical market. Their specificity for biological targets allows them to effectively treat a variety of indications. Yet, despite their successes, the various stakeholders' viewpoints in European Union (EU) countries are often at odds. We explore mAbs as a drug class, specifically, how they are approved for use by the European Medicines Agency (EMA) and other regulating bodies and how stakeholders' opinions diverge from regulatory decisions.
PHP111 ISPOR: AWARENESS, DRIVERS AND BARRIERS TO INVOLVEMENT OF UK CANCER NETWORK STAKEHOLDERS
PHP112 INTER-INDIVIDUAL COUNTRY VARIABILITY IN MONOCLONAL ANTIBODIES (MABS) REIMBURSEMENT AND COVERAGE FOLLOWING EMA APPROVAL
METHODS:
The following were summarized for mAbs approved for use in EU countries from 2000-2011: regulatory approval decisions; comparing and contrasting payer coverage decisions in selected EU countries; and position statements from patients, advocacy groups, and medical organizations. Discrepancies between initial or post-approval regulatory decisions and the statements of the other stakeholders were highlighted. RESULTS: Nineteen mAbs have been approved by the EMA during the past 10 years. The summary data show how stakeholders use clinical data to reinforce their agenda. For instance, bevacizumab has been undergoing battles in both the US and the EU: regulators want to remove specific labeled indications based on safety and effectiveness data and NICE has advised against coverage for treating metastatic colorectal cancer, citing inadequate benefits for the costs, while patients fight for continued access to the therapy to extend their life at all costs. CONCLUSIONS: After product approval, physicians have traditionally been the key treatment decision makers; however, the influence of other stakeholders are increasingly affecting the availability and use of drugs. The discordance between decisions made by regulators and payers has forced drug manufacturers to not only show that it is safe and efficacious to regulators, but to demonstrate a product's value to patients and payers. Incorporating the viewpoints of payers as well as patients in the drug development process will narrow the gap between stakeholders.
PHP113 MEASURING THE ORGANIZATIONAL PERFORMANCE IN TENNESSEE: A CASE OF COMMUNITY HOSPITALS
Roh CY, Shirore RM East Tennessee State University, Johnson City, TN, USA OBJECTIVES: Recent increase in competition among hospitals, and managed care, and the impact of Medicare Prospective Payment System; properly measured hospital performance has become important to evaluate the impact of policies on the hospital industry. This study assessed the influence of hospital governance on hospital's economic performance and efficiency, and it also attempted to systematically address the issue of 'whether participation by insider and outsider business community stakeholders on the hospital governing board is related to hospital's economic performance'. METHODS: The study was focused on 144 community hospitals in Tennessee; those provided general and acute care services from 2000 to 2006. An input-oriented and output-oriented Data Envelopment Analysis (DEA) using multiple input and output variables, which is non-parametric, flexible, and a mathematical programming approach for the performance assessment, was used to measure the efficiency by estimating the optimum level of output, conditional upon the mix of inputs. RESULTS: It was found that urban community hospitals were relatively more efficient than rural community hospitals, and smaller community hospitals were relatively more efficient than their larger and medium-sized counterparts. Interestingly, the results revealed that small-sized urban hospitals were relatively more efficient than any other community hospital type. From a management and policy perspective type, the study indicates that both rural and large community hospitals may use urban or small A353 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
